Skip to main content
SpringerLink
Log in

Phase II study of teniposide in advanced breast cancer

  • Short Communication
  • Teniposide, Advanced Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i. v. on days 1–5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH (1986) Teniposide (VM-26), an overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 4: 524–527

    Google Scholar 

  2. Cox EB, Vogel CL, Carpenter JT Jr, Raney M (1988) Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial. Invest New Drugs 6: 37–40

    Google Scholar 

  3. European Organization for Research on the Treatment of Cancer, Cooperative Group for Leukemias and Hematosarcomas (1972) Clinical screening of epipodophyllotoxin VM-26 in malignant lymphomas and solid tumors. Br Med J 2: 744–748

    Google Scholar 

  4. O'Dwyer P, Alonso MT, Leyland-Jones B, Marsoni S (1984) Teniposide: a review of 12 years of experience. Cancer Treat Rep 68: 1455–1466

    Google Scholar 

  5. Spremulli E, Schultz JJ, Speckhart VJ, Wampler GL (1980) Phase II study of VM-26 in adult malignancies. Cancer Treat Rep 64: 147–149

    Google Scholar 

  6. Tirelli U, Frenchin G, Crivellari D, Veronesi A, Galligioni E, Trovó MG, Talamini R, Tumolo S, Grigoletto E (1984) Phase II study of VM-25 in extensively pretreated breast cancer. Am J Clin Oncol 7: 451–452

    Google Scholar 

  7. WHO Handbook for Reporting Results of Cancer Treatment (1979) WHO, Geneva

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Herlev Hospital, University of Copenhagen, DK-2730, Herlev, Denmark

    Janne Boas, Dorte Rasmussen & Per Dombernowsky

  2. Department of Internal Medicine C, Bispebjerg Hospital, Copenhagen, Denmark

    Ole Paaske Hansen

  3. Department of Oncology ONK, The Finsen Institute, Copenhagen, Denmark

    Svend Aage Engelholm

Authors
  1. Janne Boas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorte Rasmussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ole Paaske Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Svend Aage Engelholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Per Dombernowsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boas, J., Rasmussen, D., Hansen, O.P. et al. Phase II study of teniposide in advanced breast cancer. Cancer Chemother. Pharmacol. 25, 463–464 (1990). https://doi.org/10.1007/BF00686061

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686061

Keywords

Search

Navigation